# 1 Title page

2 3	Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive
4	breast cancer (PERSIST): A multicenter phase II trial
5	
6	Running Title: Extended adjuvant therapy for breast cancer
7	
8	Feilin Cao <sup>1#*</sup> , Zhaosheng Ma <sup>1*</sup> , Zenggui Wu <sup>1*</sup> , Weizhu Wu <sup>2</sup> , Ouchen Wang <sup>3</sup> , Binbin Cui <sup>1&amp;</sup> , Xiaotao Zhu <sup>4&amp;</sup> ,
9	Jing Hao <sup>5^</sup> , Xiaochun Ji <sup>2^</sup> , Zhanwen Li <sup>6^</sup> , Deyou Tao <sup>1</sup> , Qingjing Feng <sup>7£</sup> , Wei Lin <sup>8£</sup> , Dongbo Shi <sup>9£</sup> , Jingde Shu <sup>8£</sup> ,
10	Jichun Zhou <sup>10</sup> , Shifen Huang <sup>1</sup>
11	
12 13	<sup>1</sup> Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China
14	<sup>2</sup> Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China
15	<sup>3</sup> Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou,
16	China
17	<sup>4</sup> Department of Thyroid and Breast Surgery, Jinhua Municipal Central Hospital, Jinhua, China
18	<sup>5</sup> Department of Thyroid and Breast Surgery, Yiwu Central Hospital, Jinhua, China
19	<sup>6</sup> Department of Breast Surgery, Ningbo Women & Children's Hospital, Ningbo, China
20	<sup>7</sup> Department of Breast Surgery, Yiwu Maternity and Children Hospital, Jinhua, China
21	<sup>8</sup> Department of Surgical Oncology, Quzhou People's Hospital, Quzhou, China
22	<sup>9</sup> Department of Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China
23	<sup>10</sup> Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
24	Hangzhou, China
25	
26	<sup>#</sup> Corresponding author:
27	Feilin Cao
28	Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University,
29	No.150 Ximen Road, Taizhou 317099, Zhejiang Province, China.
30	Email: drcfl@126.com.
31	
32	* These authors contributed equally to this work and should be considered co-first authors.
33	<sup>&amp;</sup> These authors contributed equally to this work and should be considered co-fourth authors.
34	<sup>^</sup> These authors contributed equally to this work and should be considered co-fifth authors.
35	<sup>£</sup> These authors contributed equally to this work and should be considered co-seventh authors.

#### 36 Abstract

**Background** Approximately one-third of patients with HER2-positive breast cancer experienced recurrence within 10 years after receiving 1 year of adjuvant trastuzumab. The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo. This study investigated the efficacy and safety of pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, after trastuzumab-based adjuvant therapy in patients

- 42 with high-risk, HER2-positive early or locally advanced breast cancer.
- 43 Methods This multicenter phase II trial was conducted at 23 centers in China. After enrollment, patients
- 44 received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after
- 45 the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab). The primary endpoint was
- 46 2-year iDFS rate.
- 47 **Results** Between January 2019 and February 2022, 141 eligible women were enrolled and treated. As of
- 48 October 10, 2022, the median follow-up was 24 (interquartile range, 18.0-34.0) months. The 2-year iDFS rate
- 49 was 94.59% (95% CI: 88.97-97.38) in all patients, 94.90% (95% CI: 86.97-98.06) in patients who completed
- 50 1-year treatment, 90.32% (95% CI: 72.93-96.77) in patients who completed only 6-month treatment, 96.74%
- 51 (95% CI: 87.57-99.18) in the hormone receptor-positive subgroup, 92.77% (95% CI: 83.48-96.93) in the
- 52 hormone receptor-negative subgroup, 96.88% (95% CI: 79.82-99.55) in the lymph node-negative subgroup,
- 53 93.85% (95% CI: 86.81-97.20) in the lymph node-positive subgroup, 97.30% (95% CI: 82.32-99.61) in
- 54 patients with adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06-97.02) in patients with
- adjuvant trastuzumab. The most common adverse events were diarrhea (79.4%), fatigue (36.9%), lymphocyte
- 56 count decreased (36.9%), nausea (33.3%), and hand-foot syndrome (33.3%).
- 57 Conclusion Extended adjuvant pyrotinib administrated after trastuzumab-based adjuvant therapy showed
- 58 promising efficacy in patients with high-risk HER2-positive breast cancer. The follow-up is ongoing to 59 determine the long-term benefit.
- 60 Keywords: Breast cancer; pyrotinib; human epidermal growth factor receptor 2; extended adjuvant therapy;
- 61 invasive disease-free survival
- 62

#### 63 Background

- 64 Worldwide, breast cancer is the most commonly diagnosed malignancy in women. Approximately 15-20% of 65 breast cancer cases are characterized by the overexpression of human epidermal growth factor receptor 2 66 (HER2) (1, 2). Over the past 20 years, with the emergence of HER2-targeted agents, it has been proved that the 67 addition of 1-year trastuzumab to adjuvant chemotherapy significantly reduces the recurrence rate and 68 prolongs survival in patients with HER2-positive breast cancer (3-5). However, the phase III HERA study 69 found that, despite receiving 1 year of adjuvant trastuzumab, 31% of patients with HER2-positive breast cancer experienced recurrence within 10 years (4). In addition, the phase III APHINITY study reported a 12% 70 71 recurrence rate in HER2-positive breast cancer patients with node-positive disease after receiving 1 year of
- adjuvant trastuzumab, pertuzumab and chemotherapy with a median follow-up of 74 months (6). Consequently,
- 73 novel treatment approaches are warranted to extend the time to recurrence.
- 74 Currently, the efficacy of extended adjuvant therapy has only been investigated in the phase III ExteNET study.
- 75 The results showed that 1 year of neratinib after trastuzumab-based adjuvant therapy significantly improved
- 76 invasive disease-free survival (iDFS) in women with HER2-positive breast cancer. However, the iDFS benefit
- did not translate into overall survival benefit in the intention-to-treat population after 8-year follow-up, except
- 78 for patients with hormone receptor (HR)-positive disease (7-9).
- 79 Pyrotinib is an oral irreversible pan-HER receptor tyrosine kinase inhibitor (TKI), targeting epidermal growth
- 80 factor receptor, HER2, and HER4 (10-12). For patients with HER2-positive metastatic breast cancer, improved
- 81 survival outcomes were shown in the pyrotinib group when compared with the control group in the phase III
- 82 PHOEBE and PHILA studies (13, 14). Additionally, results from the phase III PHEDRA trial demonstrated
- 83 clinical benefits of pyrotinib plus trastuzumab and docetaxel for patients with HER2-positive early or locally
- 84 advanced breast cancer in the neoadjuvant setting (15).
- 85 In the present PERSIST study, our objective was to assess the efficacy and safety of administering extended
- 86 adjuvant pyrotinib treatment following trastuzumab-based adjuvant therapy in patients with high-risk, HER2-
- 87 positive early or locally advanced breast cancer. This report presents the efficacy and safety results with a
- 88 median follow-up of 2 years, while longer follow-up is still ongoing.
- 89

#### 90 Methods

#### 91 Study design and participants

92 This multicenter, single-arm, investigator-initiated, phase II exploratory study was conducted at 23 sites in 93 China. The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang 94 Province and all other participating centers, and the trial was performed in accordance with the 2013 95 Declaration of Helsinki. This trial was registered at ClinicalTrials.gov (NCT05880927). Written informed 96 consent was obtained from all patients before study enrollment.

- Participants were eligible if they were women aged 18-75 years with high-risk, HER2-positive
  (immunohistochemistry 3+, or 2+ with gene amplification by fluorescence in situ hybridization) early or
  locally advanced invasive breast cancer; had previously completed 1 year of adjuvant therapy with either
- 100 trastuzumab or trastuzumab plus pertuzumab within 6 months before enrollment; had an Eastern Cooperative
- 101 Oncology Group performance status of 0 or 1; had known HR status; and had adequate bone marrow, hepatic,
- 102 renal and cardiac functions.
- 103 High-risk patients were defined as those meeting one of the following criteria: N stage  $\geq 1$ ; T stage  $\geq 2$ ; absence
- 104 of pathological complete response (pCR) after neoadjuvant therapy; presence of pCR after neoadjuvant therapy
- 105 but with tumor size  $\geq 5$  cm or N stage  $\geq 2$ ; tumor size  $\leq 2$  cm but with high Ki-67 level or histologic grade 3.
- 106 Clinical and pathological stage was assessed according to the eighth edition of American Joint Committee on
- 107 Cancer tumor-node-metastasis staging system. The expression of Ki-67 was categorized as low (<20%) and
- 108 high ( $\geq$ 20%) based on the ratio of positive cells to all tumor cells in 10 high-power fields.
- 109 The main exclusion criteria were bilateral breast cancer, inflammatory breast cancer, previous participation in
- 110 other clinical trials involving anticancer therapy, allergies to the drug components in this protocol, history of
- 111 immunodeficiency diseases, inability to swallow, and pregnancy or lactation.

## 112 **Procedure**

- 113 Pyrotinib 400 mg was administrated orally once daily within 6 months of completing trastuzumab-based
- adjuvant therapy. Concurrent adjuvant endocrine therapy for HR-positive disease was recommended.
- 115 Treatment duration was 12 months unless intolerable adverse events, disease recurrence, death, or consent
- 116 withdrawal occurred.

#### 117 Outcomes and assessment

118 The primary endpoint was iDFS rate at 2 years. IDFS was defined as time from the initiation of pyrotinib

119 treatment to invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local or regional

- 120 invasive recurrence, distant recurrence, or death from any cause. The secondary endpoint was safety profile,
- 121 graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version
- 122 4.0.
- Patients were followed every 3 months for the first 2 years. The follow-up assessments included physical
   examination, Eastern Cooperative Oncology Group performance status, complete blood count, blood chemistry

- 125 analysis, 12-lead electro-cardiogram, recording of adverse events, concomitant medications, and ultrasound.
- 126 Computed tomography and bone scans may be conducted if clinically indicated.
- 127 Statistical analysis
- 128 Based on the previous ExteNET trial (16), the 2-year iDFS rate was assumed as 91% in the present study. To
- 129 restrain the width of 2-sided 95% confidence interval (CI) to no more than 0.1, 126 patients were required.
- 130 Considering a dropout rate of 10%, a total of 140 participants were recruited.
- 131 Continuous data were presented as median (range or interquartile range), while categorical data were presented
- 132 as frequency (percentage). IDFS was estimated using the Kaplan-Meier method, and the corresponding 95%
- 133 CI was estimated using the Brookmeyer-Crowley method. Efficacy analysis was performed in the full analysis
- 134 set, which included all patients who received at least one dose of study drug. Safety analysis was performed in
- the safety set, defined as all patients who received at least one dose of the study drug and underwent at least
- 136 one safety assessment.

#### 138 **Results**

#### 139 Baseline characteristics

- 140 Between January 2019 and February 2022, a total of 141 eligible women were enrolled in the study and
- 141 received pyrotinib. All these patients were included in the full analysis set and safety set. The median age was
- 142 50 years (range, 25-72). Of the 141 patients, 107 (75.9%) patients had node-positive disease, and 64 (45.4%)
- had HR-positive disease. Detailed baseline characteristics are summarized in Table 1.
- 144 In terms of treatment duration, 11 patients discontinued their treatment due to adverse events, while 38 patients
- had a treatment duration of less than or equal to 6 months due to the COVID-19 pandemic or personal reasons.
- 146 A total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib,
- 147 respectively (Figure 1).

#### 148 Efficacy

- 149 As of October 10, 2022, the median follow-up duration was 24 (interquartile range, 18.0-34.0) months. Of the
- 150 141 patients, seven patients experienced iDFS events, including one local recurrence, three brain metastases,
- 151 two lung metastases, and one death due to distant metastasis. The 2-year iDFS rate was 94.59% (95% CI:
- 152 88.97-97.38; Figure 2).
- 153 Subgroup analyses showed that the 2-year iDFS rate was 94.90% (95% CI: 86.97-98.06) in the 1-year
- treatment subgroup and 90.32% (95% CI: 72.93-96.77) in the 6-month treatment subgroup (Figure 3A).
- 155 Concerning HR status, the 2-year iDFS rate was 96.74% (95% CI: 87.57-99.18) in patients with HR-positive
- breast cancer and 92.77% (95% CI: 83.48-96.93) in patients with HR-negative breast cancer (Figure 3B). In
- terms of lymph node status, the 2-year iDFS rate was 96.88% (95% CI: 79.82-99.55) in patients with lymph
- 158 node-negative breast cancer and 93.85% (95% CI: 86.81-97.20) in patients with lymph node-positive breast
- 159 cancer (Figure 3C). Regarding trastuzumab-based adjuvant regimen, the 2-year iDFS rate was 97.30% (95%
- 160 CI: 82.32-99.61) in patients who received adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06-
- 161 97.02) in patients who received adjuvant trastuzumab (Figure 3D).
- 162 Safety
- 163 The most frequently reported treatment-emergent adverse event was diarrhea (112 [79.4%]), followed by
- 164 fatigue (52 [36.9%]), lymphocyte count decreased (52 [36.9%]), nausea (47 [33.3%]), and hand-foot syndrome
- 165 (47 [33.3%]). Forty-three patients (30.5%) experienced grade 3 diarrhea, while no grade 4 or higher adverse
- 166 events was reported (Table 2). Treatment discontinuation occurred in 11 (7.8%) patients, due to grade 3
- diarrhea (n=8), grade 3 hand-foot syndrome (n=1), and intolerance (n=2). In addition, 16 patients had dose
- 168 reduction because of adverse events.
- 169

#### 170 Discussion

171 To the best of our knowledge, this multicenter phase II study is the first prospective study to explore the 172 efficacy and safety of extended adjuvant pyrotinib after trastuzumab-based adjuvant therapy in patients with 173 high-risk HER2-positive breast cancer. Furthermore, while the ExteNET study only included patients who 174 received neoadjuvant or adjuvant trastuzumab, over one-third of the patients in our study had received dual 175 anti-HER2 blockade with trastuzumab and pertuzumab, making it more clinically applicable to current clinical 176 practice (17). In China, pertuzumab was approved for the treatment of HER2-positive breast cancer in the 177 adjuvant setting in 2018, and has been covered by medical insurance since 2020. The PERSIST study started 178 in 2019, thus the proportion of eligible patients who received trastuzumab and pertuzumab in our study was 179 relatively high.

180 Currently, only neratinib has been approved by Food and Drug Administration in the extended adjuvant setting

181 for patients with HER2-positive early or locally advanced breast cancer. In the 2023 National Comprehensive 182 Cancer Network guidelines, it has been recommended for the treatment of high-risk, HR-positive, HER2-

183

positive breast cancer (18). In the ExteNET study, 1-year neratinib treatment after adjuvant trastuzumab

184 significantly improved iDFS in patients with HER2-positive breast cancer, with a 2-year iDFS rate of 93.9% in

185 the neratinib group and 91.6% in the placebo group (9, 16). In our study, the 2-year iDFS rate was 94.59%, 186 comparable to that in the ExteNET study.

187 In terms of subgroup analyses, the HR-positive group seemed to show a numerically higher 2-year iDFS rate 188 than the HR-negative group (96.74% vs. 92.77 %). Consistently, similar results were observed in the ExteNET 189 study. The underlying mechanism may involve cross-talk between HR and HER2 pathways (19, 20). 190 Preclinical studies have shown that in estrogen receptor+/HER2+ cell lines, neratinib treatment also suppresses 191 the activity of estrogen reporter (21). In the present study, adjuvant endocrine therapy was recommended for 192 patients with HR-positive disease when treated with pyrotinib, which may generate synergistic effects (22, 23). 193 Regarding duration of treatment, the results showed that the 2-year iDFS rate was numerically higher with 1-194 year pyrotinib treatment (94.90%) versus 6-month pyrotinib treatment (90.32%). In the adjuvant setting, a

195 phase III PHARE trial compared 1-year adjuvant trastuzumab with 6-month treatment, and the non-inferiority 196 was not achieved for disease-free survival. Therefore, 1-year adjuvant trastuzumab remained the standard

197 treatment (24). Further studies are warranted to find the optimal duration of extended adjuvant pyrotinib.

198 Adjuvant treatment regimens before extended adjuvant treatment may also be associated with iDFS. In the

199 present study, the 2-year iDFS rate was 93.48% and 97.30% in the trastuzumab subgroup and trastuzumab plus

200 pertuzumab subgroup, respectively. The APHINITY study demonstrated a significantly improved iDFS with

201 adjuvant trastuzumab plus pertuzumab than with adjuvant trastuzumab alone (25). Therefore, the iDFS benefits

202 may last and affect the results in the extended adjuvant period.

203 None of the patients in the PERSIST study received trastuzumab emtansine (T-DM1), which is now a standard 204 of care for HER2-positive patients with residual cancer after neoadjuvant therapy based on the phase III

KATHERINE trial (26). Since T-DM1 was approved in China in 2020 and was not covered by medical insurance until 2023, it has not been widely used in clinical practice. Recently, a real-world study showed that

207 patients with metastatic breast cancer could benefit from pyrotinib-based therapy after T-DM1 treatment (27).

208 Therefore, patients with high-risk breast cancer may also benefit from extended adjuvant pyrotinib after being

treated with T-DM1 in the adjuvant setting, which needs further investigation.

210 Regarding adverse events, diarrhea was the major safety concern in the present study, leading to treatment 211 discontinuation in eight patients. This adverse event as well as vomiting and nausea are TKI-related common 212 adverse events. The underlying mechanisms of these adverse events are not clear yet, and the mainstream 213 hypothesis is that the growth and healing of epithelial cells in gastrointestinal tract are inhibited by TKIs (28, 214 29). In the present study, 43 (30.5%) patients experienced grade 3 diarrhea, which were consistent with 215 previous studies of pyrotinib (11, 30). Noteworthy, primary prophylaxis was not mandatory in this PERSIST 216 trial. Currently, loperamide hydrochloride has been found to significantly alleviate symptoms of diarrhea and 217 reduce diarrhea-related treatment discontinuation. It has been recommended for patients treated with pyrotinib 218 (31). In the PANDORA trial of pyrotinib plus docetaxel, the incidence of diarrhea was significantly lower in 219 the loperamide prophylaxis group (8.9%) compared with the non-prophylaxis group (38.2%) (32). In the 220 CONTROL trial, all cohorts that received loperamide prophylaxis and the dose escalation cohort of neratinib 221 exhibited lower grade 3 diarrhea rates and fewer instances of diarrhea-related treatment discontinuation 222 compared with ExteNET (33). The above two studies indicated that pyrotinib-related diarrhea could be 223 controlled with prophylaxis or dose modification.

- 224 There are several limitations in the present study. Firstly, our study was a single-arm study without control
- group. Secondly, patients who received T-DM1 therapy in the adjuvant setting were not enrolled. Thirdly, 27.0%
- of patients did not complete 1-year extended adjuvant pyrotinib due to COVID-19 pandemic or personal
- reasons. Finally, the follow-up time was short. A phase III clinical trial (NCT03980054) of extended adjuvant
- 228 pyrotinib in patients with high-risk HER2-positive breast cancer is ongoing, which will further demonstrate the
- 229 efficacy of extended adjuvant TKI and bring new hope for patients with high-risk HER2-positive breast cancer.
- 230 Conclusions
- Our study suggests the potential of extended adjuvant pyrotinib in patients with high-risk HER2-positive early or locally advanced breast cancer after trastuzumab-based adjuvant therapy. The follow-up is ongoing to determine the long-term benefit of extended adjuvant pyrotinib.
- 234

# 235 Author contributions

236 Huigiang Huang: Conceptualization (Equal); Resources (Equal); Visualization (Equal); Zhaosheng Ma: 237 Conceptualization (Equal); Investigation (Equal); Writing – original draft (Equal); Zenggui Wu: Investigation 238 (Equal); Methodology (Equal); Writing - original draft (Equal); Weizhu Wu: Formal analysis (Equal); 239 Methodology (Equal); Software (Equal); Writing – original draft (Equal); Ouchen Wang: Methodology 240 (Equal); Resources (Equal); Writing – review & editing (Equal); Binbin Cui: Investigation (Equal); Project 241 administration (Equal); Software (Equal); Xiaotao Zhu: Investigation (Equal); Resources (Equal); Writing – 242 original draft (Equal); Jing Hao: Investigation (Equal); Writing - original draft (Equal); Writing - review & 243 editing (Equal); Xiaochun Ji: Conceptualization (Equal); Supervision (Equal); Zhanwen Li: Methodology 244 (Equal); Project administration (Equal); Resources (Equal); Deyou Tao: Software (Equal); Validation (Equal); 245 Qingjing Feng: Methodology (Equal); Supervision (Equal); Validation (Equal); Writing - original draft (Equal); Wei Lin: Methodology (Equal); Supervision (Equal); Writing - original draft (Equal); Writing -246 247 review & editing (Equal); Dongbo Shi: Supervision (Equal); Validation (Equal); Visualization (Equal); 248 Writing – original draft (Equal); Writing – review & editing (Equal); Jingde Shu: Software (Equal); Writing – 249 review & editing (Equal); Jichun Zhou: Methodology (Equal); Supervision (Equal); Validation (Equal); 250 Writing – review & editing (Equal); Shifen Huang: Resources (Equal); Writing – review & editing (Equal)

# 251 Acknowledgements

252 We thank all the patients who participated in this trial and their families, as well as the investigators and staff.

253 We thank Yan Luo (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for data

254 interpretation and Yunning Yang (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.)

255 for medical writing assistance according to Good Publication Practice Guidelines.

256 Funding

257 None.

258 Conflict of interest statement

259 The authors declare no conflict of interests.

#### 260 Ethics approval and consent to participate

The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang Province and all other participating centers, and the trial was performed in accordance with the 2013 Declaration of Helsinki. Written informed consent was obtained from all participants.

#### 264 Clinical trial registration number

- 265 This trial was registered at ClinicalTrials.gov (NCT05880927).
- 266 Data availability statement
- Data supporting the findings of this study are available from the corresponding author upon reasonable request.
- 269

270	References
271	1 Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA: a Cancer Journal For
272	Clinicians 64(1), 2014. PMID: Q1, DOI: 10.3322/caac.21208
273	2 Loibl S and Gianni L: Her2-positive breast cancer. Lancet (London, England)
274	389(10087): 2415-2429, 2017. PMID: Q1, DOI: 10.1016/S0140-6736(16)32417-5
275	3 Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, Martino S, Rastogi
276	P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E,
277	Zujewski JA and Wolmark N: Trastuzumab plus adjuvant chemotherapy for human
278	epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of
279	overall survival from nsabp b-31 and ncctg n9831. Journal of Clinical Oncology : Official
280	Journal of the American Society of Clinical Oncology <i>32(33)</i> : 3744-3752, 2014. PMID:
281 282	Q1, DOI: 10.1200/JCO.2014.55.5730
282 283	4 Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E,
283 284	Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M and Jackisch C: 11 years' follow-up of trastuzumab
285	after adjuvant chemotherapy in her2-positive early breast cancer: Final analysis of the
285	herceptin adjuvant (hera) trial. Lancet (London, England) 389(10075): 1195-1205, 2017.
287	PMID: Q1, DOI: 10.1016/S0140-6736(16)32616-2
288	5 Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred
289	DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S,
290	Perez EA, Press MF, Spears PA, Vance GH, Viale G and Hayes DF: Recommendations
291	for human epidermal growth factor receptor 2 testing in breast cancer: American society
292	of clinical oncology/college of american pathologists clinical practice guideline update.
293	Journal of Clinical Oncology : Official Journal of the American Society of Clinical
294	Oncology 31(31): 3997-4013, 2013. PMID: Q1, DOI: 10.1200/JCO.2013.50.9984
295	6 Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E,
296	Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu T-W, Pieńkowski T, Toi M,
297	Wilcken N, Andersson M, Im Y-H, Tseng LM, Lueck H-J, Colleoni M, Monturus E,
298	Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G and Thomssen C: Adjuvant
299	pertuzumab and trastuzumab in early her2-positive breast cancer in the aphinity trial: 6
300	years' follow-up. Journal of Clinical Oncology : Official Journal of the American Society
301	of Clinical Oncology <i>39(13)</i> : 1448-1457, 2021. PMID: Q1, DOI: 10.1200/JCO.20.01204
302 303	7 Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyge M, Barries CH, Silovski T, Šenerović B, Bashford A, Zotano AG, Denduluri N
303 304	Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW, Loibl S, Masuda N, Tomašević Z, Petráková K,
304	DiPrimeo D, Wong A, Martin M and Chan A: Overall survival with neratinib after
306	trastuzumab-based adjuvant therapy in her2-positive breast cancer (extenet): A
307	randomised, double-blind, placebo-controlled, phase 3 trial. European Journal of Cancer
308	(Oxford, England : 1990) 184(48-59, 2023. PMID: Q1, DOI: 10.1016/j.ejca.2023.02.002
309	8 Lüftner D, Tesch H, Schmidt M, Hartkopf AD, Streicher S, Resch A, Genovese L, Rosé
310	C, Valenti R and Harbeck N: Neratinib as extended adjuvant therapy in patients with
311	copositive early breast cancer: German health technology assessment-driven analyses
312	from the extend study. European Journal of Cancer (Oxford, England : 1990) 150(268-
313	277, 2021. PMID: Q1, DOI: 10.1016/j.ejca.2021.03.045
314	9 Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G,
315	Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R,

316	Gokmen E, Bashford A, Ruiz Borrego M, Kim S-B, Jakobsen EH, Ciceniene A, Inoue K,
317	Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S,
318	Yao B, Xu F, Auerbach A, Buyse M and Chan A: Neratinib after trastuzumab-based
319	adjuvant therapy in her2-positive breast cancer (extenet): 5-year analysis of a randomised,
320	double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 18(12): 1688-1700,
321	2017. PMID, DOI:
322	10 Blair HA: Pyrotinib: First global approval. Drugs 78(16): 1751-1755, 2018. PMID,
323	DOI: 10.1007/s40265-018-0997-0
324	11 Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, Hu X,
325	Zou J, Zhu X and Xu B: Pyrotinib or lapatinib combined with capecitabine in her2-
326	positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab:
327	A randomized, phase ii study. Journal of Clinical Oncology : Official Journal of the
328	American Society of Clinical Oncology 37(29): 2610-2619, 2019. PMID: Q1, DOI:
329	10.1200/JCO.19.00108
330	12 Guan X, Ma F, Li Q, Chen S, Lan B, Fan Y, Wang J, Luo Y, Cai R, Zhang P, Li Q
331	and Xu B: Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus
332	capecitabine for patients with her2-positive metastatic breast cancer: A pooled analysis of
333	two phase i studies. Biomarker Research $11(1)$ : 21, 2023. PMID: Q1, DOI:
334	10.1186/s40364-023-00453-0
335	13 Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang
336	X, Yin Y, Cheng Y, Li W, Gu Y, Chen Q, Liu J, Cheng J, Geng C, Qin S, Wang S, Lu J,
337	Shen K, Liu Q, Wang X, Wang H, Luo T, Yang J, Wu Y, Yu Z, Zhu X, Chen C and Zou
338	J: Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of her2-
339	positive metastatic breast cancer (phoebe): A multicentre, open-label, randomised,
340	controlled, phase 3 trial. The Lancet Oncology 22(3): 351-360, 2021. PMID: Q1, DOI:
340	10.1016/S1470-2045(20)30702-6
342	14 Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line
343	treatment in patients with her2 positive metastatic breast cancer (phila): Randomised,
344	double blind, multicentre, phase 3 trial. BMJ (Clinical Research ed) 383(p2665, 2023.
345	PMID: Q1, DOI: 10.1136/bmj.p2665
345	15 Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang
340	S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X
348	and Zou J: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for her2-positive breast
349	cancer (phedra): A double-blind, randomized phase 3 trial. BMC Medicine 20(1): 498,
350	2022. PMID: Q1, DOI: 10.1186/s12916-022-02708-3
351	16 Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T,
352	Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M,
353	Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N,
354	Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B and Martin M: Neratinib after
355	trastuzumab-based adjuvant therapy in patients with her2-positive breast cancer (extenet):
356	A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet
357	Oncology <i>17(3)</i> : 367-377, 2016. PMID: Q1, DOI: 10.1016/S1470-2045(15)00551-3
358	17 Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn
359	HJ, Winer EP and Gnant M: Customizing local and systemic therapies for women with
360	early breast cancer: The st. Gallen international consensus guidelines for treatment of
361	early breast cancer 2021. Annals of Oncology : Official Journal of the European Society

362	For Medical Oncology 32(10): 1216-1235, 2021. PMID: Q1, DOI:
363	10.1016/j.annonc.2021.06.023
364	18 Bevers TB, Niell BL, Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S,
365	Conant EF, Eghtedari M, Flanagan MR, Hawley J, Helvie M, Hodgkiss L, Hoyt TL,
366	Ivanovich J, Jochelson MS, Kulkarni S, Lancaster RB, Mauer C, Maxwell J, Patel BK,
367	Pearlman M, Philpotts L, Plecha D, Plichta JK, Shakeri S, Smith ML, Streibert CL,
368	Strigel RM, Tumyan L, Winkler NS, Wolverton DE, Bergman MA, Kumar R and
369	Stehman K: Nccn guidelines® insights: Breast cancer screening and diagnosis, version
370	1.2023. Journal of the National Comprehensive Cancer Network : JNCCN 21(9): 900-
371	909, 2023. PMID: Q1, DOI: 10.6004/jnccn.2023.0046
372	19 Nahta R and O'Regan RM: Therapeutic implications of estrogen receptor signaling in
373	her2-positive breast cancers. Breast Cancer Research and Treatment 135(1): 39-48, 2012.
374	PMID: Q2, DOI: 10.1007/s10549-012-2067-8
375	20 Pegram M, Jackisch C and Johnston SRD: Estrogen/her2 receptor crosstalk in breast
376	cancer: Combination therapies to improve outcomes for patients with hormone receptor-
377	positive/her2-positive breast cancer. NPJ Breast Cancer 9(1): 45, 2023. PMID: Q1, DOI:
378	10.1038/s41523-023-00533-2
379	21 Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S,
380	González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS,
381	Bryce R, Auerbach A and Arteaga CL: Extended adjuvant therapy with neratinib plus
382	fulvestrant blocks er/her2 crosstalk and maintains complete responses of er+/her2+ breast
383	cancers: Implications to the extenet trial. Clinical Cancer Research : an Official Journal
384	of the American Association For Cancer Research 25(2): 771-783, 2019. PMID: Q1, DOI:
385	10.1158/1078-0432.CCR-18-1131
386	22 Hu Z-Y, Yan M, Xiong H, Ran L, Zhong J, Luo T, Sun T, Xie N, Liu L, Yang X,
387	Xiao H, Li J, Liu B and Ouyang Q: Pyrotinib in combination with letrozole for hormone
388	receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast
389	cancer (pleherm): A multicenter, single-arm, phase ii trial. BMC Medicine $21(1)$ : 226,
390	2023. PMID: Q1, DOI: 10.1186/s12916-023-02943-2
391	23 Zhang J, Meng Y, Wang B, Wang L, Cao J, Tao Z, Li T, Yao W and Hu X:
392	Dalpiciclib combined with pyrotinib and letrozole in women with her2-positive, hormone
393	receptor-positive metastatic breast cancer (lordships): A phase ib study. Frontiers In
394	Oncology 12(775081, 2022. PMID: Q2, DOI: 10.3389/fonc.2022.775081
395	24 Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, Lortholary A, Espié
396	M, Fumoleau P, Serin D, Jacquin J-P, Jouannaud C, Rios M, Abadie-Lacourtoisie S,
397	Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C,
398	Paget-Bailly S, Henriques J and Grouin JM: 6 months versus 12 months of adjuvant
399	trastuzumab in early breast cancer (phare): Final analysis of a multicentre, open-label,
400	phase 3 randomised trial. Lancet (London, England) 393(10191): 2591-2598, 2019.
400	PMID: Q1, DOI: 10.1016/S0140-6736(19)30653-1
402	25 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G,
403	Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines
403	J, Gelber RD, Piccart M and Baselga J: Adjuvant pertuzumab and trastuzumab in early
405	her2-positive breast cancer. The New England journal of medicine 377(2): 122-131, 2017.
403	PMID, DOI: 10.1056/NEJMoa1703643
<del>-1</del> 00	1 WILD, DOI: 10.1030/10D31/03043

<ul> <li>N. Rastogi P. Schneeweiss A. Redondo A. Fischer HH, Jacota W. Conlin AK, Arce-</li> <li>Shao Z., Rota Caremoli E., Wu H, Lam LH, Tesarowski D, Smitt M, Douhwaite H, Singel</li> <li>SM and Geyer CE: Trastuzumab entansine for residual invasive her2-positive breast</li> <li>cancer. The New England Journal of Medicine <i>380</i>(7): 617-628, 2019. PMID: Q1, DOI:</li> <li>10.1056/NEJMoa1814017</li> <li>27 Liang X., Gui X., Yan Y., Di L, Liu X, Li H and Song G: Long-term outcome analysis</li> <li>of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis:</li> <li>a real-world study. The Oncologist <i>29</i>(2): e198-e205, 2024. PMID: Q1, DOI:</li> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capacitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive davaced breast cancer patients. Annals of Palliative Medicine <i>11</i>(<i>1</i>): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li L, Li M, Chen Z a</li></ul>	407	26 von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark
<ul> <li>Salinas Č, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P,</li> <li>Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel</li> <li>SM and Geyer CE: Trastuzumab emtansine for residual invasive her2-positive breast</li> <li>cancer. The New England Journal of Medicine <i>380</i>(7): 617-628, 2019. PMID: Q1, DOI:</li> <li>10.1056/NEJMoa1814017</li> <li>27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis</li> <li>of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis:</li> <li>A real-world study. The Oncologist <i>29</i>(2): e198-e205, 2024. PMID: Q1, DOI:</li> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy <i>8</i>(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11</i>(<i>1</i>): 210-216, 2022. PMID, DOI: 10.2037/apm-21-3978</li> <li< td=""><td></td><td></td></li<></ul>		
<ul> <li>Shao Z, Rota Čaremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM and Geyer CE: Trastuzumab emtansine for residual invasive her2-positive breast cancer. The New England Journal of Medicine <i>380(7)</i>: 617-628, 2019. PMID: Q1, DOI: 10.1056/NEJMoa1814017</li> <li>27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis: A real-world study. The Oncologist <i>29(2)</i>: e198-e205, 2024. PMID: Q1, DOI: 10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy <i>8(1)</i>: 262, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: Diarthea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies <i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8(1)</i>: 118, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of Palliative Medicine <i>11(1)</i>: 210-216, 2022. PMID, DOI: 10.2103/ngm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-positive metastatic breast cancer: The pandora phase it trial. Nature Communications <i>14(1)</i>: 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-</li></ul>		
<ul> <li>SM and Geyer CE: Trastuzumab emtansine for residual invasive her2-positive breast cancer. The New England Journal of Medicine 380(7): 617-628, 2019. PMID: Q1, DOI: 10.1056/NEJMoa1814017</li> <li>Z1 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis: A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI: 10.1093/oncolo/oyad228</li> <li>Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies 19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive advanced breats cancer patients. Annals of Palliative Medicine 11(1): 210-216, 2022. PMID. DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2- positive metastatic breast cancer: The pandora phase ii trial. Nature Communications 14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Ma</li></ul>		
<ul> <li>cancer. The New England Journal of Medicine 380(7): 617-628, 2019. PMID: Q1, DOI:</li> <li>10.1056/NEJMoa1814017</li> <li>27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis</li> <li>of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis:</li> <li>A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI:</li> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Can Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz</li></ul>		
<ul> <li>10.1056/NEJMoa1814017</li> <li>27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis: A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI: 10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies 19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-positive metastatic breast cancer: The pandora phase it itial. Nature Communications 14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Livak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D an</li></ul>		
<ul> <li>27 Liang X, Gui X, Yan Y, Di L, Liu X, Li H and Song G: Long-term outcome analysis of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis:</li> <li>A real-world study. The Oncologis 29(2): e198-e205, 2024. PMID: Q1, DOI: 10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies 19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2- positive metastatic breast cancer: The pandora phase ii trial. Nature Communications 14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saarz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D and Chan A: Im</li></ul>		•
<ul> <li>of pyrotinib in patients with her2-positive metastatic breast cancer and brain metastasis:</li> <li>A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI:</li> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bry</li></ul>		
<ul> <li>A real-world study. The Oncologist 29(2): e198-e205, 2024. PMID: Q1, DOI:</li> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chian AJ, Iannoti N, Marx G,</li> <li>Hurtyfsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in p</li></ul>		
<ul> <li>10.1093/oncolo/oyad228</li> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase</li> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. An</li></ul>		
<ul> <li>28 Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI: 10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM: Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies 19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B: Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2- positive metastatic breast cancer: The pandora phase ii trial. Nature Communications 14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Bruťsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with her2-positive early-stage breast cancer: The control trial. Annals of oncology : official journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID, DOI:</li> </ul>		
<ul> <li>inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.</li> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,<!--</td--><td></td><td></td></li></ul>		
<ul> <li>Signal Transduction and Targeted Therapy 8(1): 262, 2023. PMID: Q1, DOI:</li> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li>19(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>10.1038/s41392-023-01469-6</li> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11</i>(<i>1</i>): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14</i>(<i>1</i>): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31</i>(<i>9</i>): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>29 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ and Bowen JM:</li> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11</i>(<i>1</i>): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14</i>(<i>1</i>): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31</i>(<i>9</i>): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		<b>o i</b> , <b>i</b>
<ul> <li>Diarrhea induced by small molecule tyrosine kinase inhibitors compared with</li> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11</i>(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14</i>(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31</i>(<i>9</i>): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies</li> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11(1)</i>: 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14(1)</i>: 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li><i>19</i>(1534735420928493, 2020. PMID: Q2, DOI: 10.1177/1534735420928493</li> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy <i>8</i>(<i>1</i>): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine <i>11</i>(<i>1</i>): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14</i>(<i>1</i>): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31</i>(<i>9</i>): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>30 Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y, Zhang P, Li Q and Xu B:</li> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>Pyrotinib plus capecitabine could significantly improve overall survival in her2-positive</li> <li>metastatic breast cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>metastatic breat cancer. Signal Transduction and Targeted Therapy 8(1): 118, 2023.</li> <li>PMID: Q1, DOI: 10.1038/s41392-023-01322-w</li> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
429PMID: Q1, DOI: 10.1038/s41392-023-01322-w43031 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of431pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of432Palliative Medicine $11(1)$ : 210-216, 2022. PMID, DOI: 10.21037/apm-21-397843332 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,434Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-435positive metastatic breast cancer: The pandora phase ii trial. Nature Communications436 $14(1)$ : 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y43733 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,438Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,440Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with441her2-positive early-stage breast cancer: The control trial. Annals of oncology : official442journal of the European Society for Medical Oncology $31(9)$ : 1223-1230, 2020. PMID,443DOI:		
<ul> <li>31 Fang C, Wen J, Kang M, Zhang Y, Chen Q and Ren L: Incidence and management of</li> <li>pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of</li> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
431pyrotinib-associated diarrhea in her2-positive advanced breast cancer patients. Annals of432Palliative Medicine $11(1)$ : 210-216, 2022. PMID, DOI: 10.21037/apm-21-397843332 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,434Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-435positive metastatic breast cancer: The pandora phase ii trial. Nature Communications436 $14(1)$ : 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y43733 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,438Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,439Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,440Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with441her2-positive early-stage breast cancer: The control trial. Annals of oncology : official443DOI:		
<ul> <li>Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978</li> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li>14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology 31(9): 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,</li> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14(1)</i>: 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		
<ul> <li>Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-</li> <li>positive metastatic breast cancer: The pandora phase ii trial. Nature Communications</li> <li><i>14(1)</i>: 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y</li> <li>Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>		Palliative Medicine 11(1): 210-216, 2022. PMID, DOI: 10.21037/apm-21-3978
435positive metastatic breast cancer: The pandora phase ii trial. Nature Communications436 $14(1)$ : 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y43733 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,438Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,439Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,440Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with441her2-positive early-stage breast cancer: The control trial. Annals of oncology : official442journal of the European Society for Medical Oncology $31(9)$ : 1223-1230, 2020. PMID,443DOI:	433	32 Zheng Y, Cao W-M, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X,
<ul> <li>436</li> <li>436</li> <li>437</li> <li>438</li> <li>438</li> <li>439</li> <li>439</li> <li>439</li> <li>430</li> <li>430</li> <li>430</li> <li>431</li> <li>431</li> <li>431</li> <li>441</li> <li>441</li></ul>	434	Li H, Li M, Chen Z and Wang X: Pyrotinib plus docetaxel as first-line treatment for her2-
<ul> <li>33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,</li> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	435	positive metastatic breast cancer: The pandora phase ii trial. Nature Communications
<ul> <li>Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,</li> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	436	14(1): 8314, 2023. PMID: Q1, DOI: 10.1038/s41467-023-44140-y
<ul> <li>Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,</li> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	437	33 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G,
<ul> <li>Rugo HS, Tripathy D and Chan A: Improved tolerability of neratinib in patients with</li> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	438	Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y,
<ul> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	439	Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L,
<ul> <li>her2-positive early-stage breast cancer: The control trial. Annals of oncology : official</li> <li>journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>DOI:</li> </ul>	440	
<ul> <li>442 journal of the European Society for Medical Oncology <i>31(9)</i>: 1223-1230, 2020. PMID,</li> <li>443 DOI:</li> <li>444</li> </ul>	441	her2-positive early-stage breast cancer: The control trial. Annals of oncology : official
443 DOI: 444		
444		
	445	

446 **Table 1.** Baseline characteristics of patients in the full analysis set

Variables	All (n=141)
Age (years), median (range)	50 (25-72)
T stage, n (%)	
T1	43 (30.5%)
T2	83 (58.9%)
T3	11 (7.8%)
T4	2 (1.4%)
Unable to determine	2 (1.4%)
Nodal status, n (%)	
Negative	34 (24.1%)
1-3 positive nodes	49 (34.8%)
>3 positive nodes	58 (41.1%)
Hormone receptor status, n (%)	
Negative (ER and PR negative)	77 (54.6%)
Positive (ER positive, PR positive, or both)	64 (45.4%)
Ki-67, n (%)	
≥20%	119 (84.4%)
<20%	22 (15.6%)
Previous neoadjuvant therapy, n (%)	26 (17.7%)
Previous adjuvant therapy, n (%)	· ·
Trastuzumab	92 (65.2%)
Trastuzumab plus pertuzumab	49 (34.8%)

447 ER, estrogen receptor; PR, progesterone receptor.

448 Tumors were assessed as being ER or PR positive with a threshold of 1%.

Events, n (%)	All (n=141)	
	Any grade	Grade 3
Diarrhea	112 (79.4%)	43 (30.5%)
Fatigue	52 (36.9%)	0
Lymphocyte count decreased	52 (36.9%)	0
Nausea	47 (33.3%)	0
Hand-foot syndrome	47 (33.3%)	1 (0.7%)
Hyperuricemia	33 (23.4%)	0
White blood cell count decreased	26 (18.4%)	0
Dizziness	26 (18.4%)	0
Anemia	24 (17.0%)	0
Vomiting	22 (15.6%)	0
Headache	19 (13.5%)	0
Creatinine increased	17 (12.1%)	0
Neutrophil count decreased	16 (11.3%)	0

450	Table 2. Treatment-emergent adverse even	ents occurring in at least 10% of the patients.
-----	--	---

451

# 453 **Figure legends**

- 454 **Figure 1.** Study flowchart.
- 455 **Figure 2.** Invasive disease-free survival in the full analysis set.

456 Figure 3. Invasive disease-free survival in subgroups. (A) Treatment duration of pyrotinib (1

457 year vs. 6 months). (B) Hormone receptor status (positive vs. negative). (C) Node status (positive

458 vs. negative). (D) Adjuvant regimen before extended adjuvant pyrotinib (trastuzumab vs.

- 459 trastuzumab plus pertuzumab).
- 460
- 461











